Browsing by Author "Cripe, Larry"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
    (Springer, 2008-05) Giagounidis, Aristoteles; Fenaux, Pierre; Mufti, Ghulam J.; Muus, Petra; Platzbecker, Uwe; Sanz, Guillermo; Cripe, Larry; Von Lilienfeld-Toal, Marie; Wells, Richard A.; Medicine, School of Medicine
    Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q (del(5q)) cytogenetic abnormality. Although some patients with del(5q) have a relatively good prognosis, all del(5q) patients will become transfusion-dependent at some point during the course of their disease. The results of two clinical trials in more than 160 patients with MDS have demonstrated clear therapeutic benefits of lenalidomide, with >60% of patients achieving independence from transfusion during therapy, irrespective of age, prior therapy, sex, or disease-risk assessment. The recommendations presented in this review will aid the safe administration of lenalidomide for the treatment of patients with low-risk or intermediate-1-risk MDS and a del(5q) cytogenetic abnormality, and they will help physicians avoid unnecessary dose reduction or interruption, thus assuring the best efficacy for patients.
  • Thumbnail Image
    Item
    Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
    (Springer, 2008-05) Giagounidis, Aristoteles; Fenaux, Pierre; Mufti, Ghulam J.; Muus, Petra; Platzbecker, Uwe; Sanz, Guillermo; Cripe, Larry; Von Lilienfeld-Toal, Marie; Wells, Richard A.; Medicine, School of Medicine
    Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q (del(5q)) cytogenetic abnormality. Although some patients with del(5q) have a relatively good prognosis, all del(5q) patients will become transfusion-dependent at some point during the course of their disease. The results of two clinical trials in more than 160 patients with MDS have demonstrated clear therapeutic benefits of lenalidomide, with >60% of patients achieving independence from transfusion during therapy, irrespective of age, prior therapy, sex, or disease-risk assessment. The recommendations presented in this review will aid the safe administration of lenalidomide for the treatment of patients with low-risk or intermediate-1-risk MDS and a del(5q) cytogenetic abnormality, and they will help physicians avoid unnecessary dose reduction or interruption, thus assuring the best efficacy for patients.